Bfsg LLC Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Bfsg LLC acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,500 shares of the company’s stock, valued at approximately $30,000.

A number of other hedge funds have also recently modified their holdings of FDMT. RA Capital Management L.P. boosted its stake in shares of 4D Molecular Therapeutics by 35.6% in the third quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock worth $52,998,000 after buying an additional 1,093,680 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth about $2,887,000. Panagora Asset Management Inc. purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter worth about $964,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth about $966,000. Finally, Trexquant Investment LP purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter worth about $566,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on FDMT shares. Royal Bank of Canada upped their target price on 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Barclays started coverage on 4D Molecular Therapeutics in a research report on Monday, April 15th. They set an “overweight” rating on the stock. The Goldman Sachs Group reiterated a “buy” rating and set a $81.00 price target on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, March 1st. Finally, Jefferies Financial Group increased their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $44.22.

4D Molecular Therapeutics Stock Down 3.0 %

NASDAQ:FDMT opened at $23.53 on Friday. The company has a market capitalization of $1.20 billion, a P/E ratio of -8.85 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a 52 week low of $9.44 and a 52 week high of $36.25. The stock’s fifty day moving average is $28.68 and its two-hundred day moving average is $20.57.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, February 29th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The company had revenue of ($0.02) million for the quarter, compared to analyst estimates of $4.67 million. 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. Sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 6,244 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $27.50, for a total transaction of $171,710.00. Following the completion of the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at approximately $47,767.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO David Kirn sold 92,001 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $27.13, for a total value of $2,495,987.13. Following the completion of the sale, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $28,734,820.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Bizily sold 6,244 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $27.50, for a total value of $171,710.00. Following the completion of the sale, the insider now directly owns 1,737 shares of the company’s stock, valued at $47,767.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 143,942 shares of company stock valued at $4,074,435. 10.70% of the stock is currently owned by corporate insiders.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.